Non-IgG Antibodies Explained: Why IgA/IgM/IgE Are Re-Emerging in Biologics Design
IgG has been the “default chassis” for therapeutic antibodies for decades—and for good reason: mature discovery workflows, predictable developability, well-characterized Fc effector biology, and scalable manufacturing. But the industry’s IgG-centric comfort zoneRead More…